Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Retinal Dystrophy and Oncology Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for TTLL5 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | TTLL5 Recombinant Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. Sf9/HEK293 expressed to preserve post-translational modifications. |
View TTLL5 Products |
| Gene Delivery | TTLL5 Promise-ORF / Lentivirus Full-length human TTLL5 ORF for stable cell line construction and in vitro tubulin glutamylation assays. |
View TTLL5 Products |
| Benchmark Ab | Anti-TTLL5 Recombinant Antibody Recombinant positive control for Western Blot, IHC, and immunoprecipitation assays. |
View TTLL5 Products |
| Validator | TTLL5 siRNA Set Target-specific siRNA pool for gene knockdown and functional assay validation. |
View TTLL5 Products |
| Related Target A | TTLL6 Tubulin polyglutamylase acting synergistically with TTLL5; critical for selectivity and counter-screening panels. |
View TTLL6 Products |
| Related Target B | TUBB3 Beta-tubulin isotype III; key substrate for TTLL5-mediated glutamylation in neuronal and tumor cells. |
View TUBB3 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Enzymatic Activity & Stability | Sf9/HEK293 eukaryotic expression ensures correct folding of the large TTLL5 catalytic domain. |
| Subfamily Cross-Reactivity | Homolog screening panel including TTLL6 and TTLL1 to verify inhibitor selectivity. |
| Lack of Controls | Sequence-verified clinical-grade benchmark antibodies included in the catalog. |
| False Positives in Knockdown | HPLC-purified, sequence-validated siRNA pools for target specificity confirmation. |
Live TTLL5 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for TTLL5 therapeutics is intensifying, with major players shifting focus from traditional small-molecule inhibitors to gene therapy vectors and targeted microtubule-modulating agents. As first-generation therapies for retinal dystrophies reach preclinical validation, the next wave of R&D is targeting TTLL5-mediated tubulin polyglutamylation in oncology, particularly in taxane-resistant solid tumors where microtubule dynamics are altered.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Gene Therapy (AAV) | Academic Medical Centers, Biotech Startups | Retinitis Pigmentosa, Cone-Rod Dystrophy | Transgene expression validation (Need high-purity TTLL5 protein & qPCR/WB control antibodies) |
| Small Molecule Inhibitor | Oncology-focused Biopharma | Chemoresistant Cancers (Breast, Prostate) | Selectivity assay (Need recombinant TTLL5, TTLL6, and TTLL1 proteins for differential screening) |
| RNA Therapeutics | Ocular Gene Therapy Developers | Inherited Retinal Diseases (IRD) | Target knockdown and rescue verification (Need validated TTLL5 siRNA & Lentivirus) |